​

Unicycive Therapeutics Stock (NASDAQ:UNCY)

ForecastOwnershipFinancialsChart
Unicycive Therapeutics by TradingView

Previous Close

$6.92

52W Range

$3.71 - $11.00

50D Avg

$5.97

200D Avg

$5.35

Market Cap

$147.86M

Avg Vol (3M)

$473.00K

Beta

1.84

Div Yield

-

UNCY Company Profile

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

22

IPO Date

Jul 12, 2021

Website

UNCY Performance

UNCY Financial Summary

Dec 24Dec 23Dec 22
Revenue-$675.00K$951.00K
Operating Income$-32.12M$-20.77M$-18.05M
Net Income$-37.82M$-30.54M$-18.06M
EBITDA$-32.12M$-30.18M$-18.05M
Basic EPS$-0.06$-1.28$-1.20
Diluted EPS$-0.06$-1.28$-1.20

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
HYFTMindWalk Holdings Corp.
CAMPCAMP4 Therapeutics Corporation
RPTXRepare Therapeutics Inc.
PMVPPMV Pharmaceuticals, Inc.
BMEABiomea Fusion, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
IMUXImmunic, Inc.
RLMDRelmada Therapeutics, Inc.
CBUSCibus, Inc.
VXRTVaxart, Inc.